Terlipressin
Terlivaz (terlipressin) is a protein pharmaceutical. Terlipressin was first approved as Terlivaz on 2022-09-14.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Terlivaz
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Terlipressin acetate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TERLIVAZ | Mallinckrodt | N-022231 RX | 2022-09-14 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| terlivaz | New Drug Application | 2024-04-15 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
TERLIPRESSIN ACETATE, TERLIVAZ, MALLINCKRODT IRELAND | |||
| 2029-09-14 | ODE-406 | ||
| 2027-09-14 | NCE | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Terlipressin Acetate, Terlivaz, Mallinckrodt Ireland | |||
| 10335452 | 2037-04-05 | U-3711 | |
HCPCS
No data
Clinical
Clinical Trials
107 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatorenal syndrome | D006530 | — | K76.7 | — | — | 3 | — | — | 3 |
| Syndrome | D013577 | — | — | — | — | 3 | — | — | 3 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | 1 | — | — | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Terlipressin |
| INN | terlipressin |
| Description | Terlipressin is a polypeptide. |
| Classification | Protein |
| Drug class | vasoconstrictors (vasopressin derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O |
Identifiers
| PDB | — |
| CAS-ID | 14636-12-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2135460 |
| ChEBI ID | — |
| PubChem CID | 72081 |
| DrugBank | DB02638 |
| UNII ID | 7Z5X49W53P (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,518 documents
View more details
Safety
Black-box Warning
Black-box warning for: Terlivaz
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
120 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use